We are live on ! Find out more
AC

Armistice Capital Portfolio holdings

AUM $5.62B
1-Year Est. Return 36.06%
This Fund
S&P 500
This Quarter Est. Return
+2.27%
1 Year Est. Return
+36.06%
3 Year Est. Return
+44.14%
5 Year Est. Return
+38.37%
10 Year Est. Return
+188.88%
AUM
$7.33B
AUM Growth
+$1.08B
Cap. Flow
+$1.18B
Cap. Flow %
16.06%
Top 10 Hldgs %
55.65%
Holding
321
New
63
Increased
80
Reduced
61
Closed
90

Top Buys

Rank Stock Value
1
EXAS
Exact Sciences
EXAS
+$101M
2
ICLR icon
Icon
ICLR
+$97.6M
3
NBIX icon
Neurocrine Biosciences
NBIX
+$87.9M
4
VRTX icon
Vertex Pharmaceuticals
VRTX
+$82.5M
5
GSK icon
GSK
GSK
+$66.7M

Top Sells

Rank Stock Value
1
ALKS icon
Alkermes
ALKS
+$40.5M
2
PTCT icon
PTC Therapeutics
PTCT
+$36.7M
3
SHAK icon
Shake Shack
SHAK
+$32.9M
4
INCY icon
Incyte
INCY
+$30.5M
5
CYTK icon
Cytokinetics
CYTK
+$30.4M

Sector Composition

Rank Sector Weight
1 Healthcare 39.34%
2 Consumer Discretionary 6.39%
3 Consumer Staples 5.37%
4 Technology 5.27%
5 Communication Services 0.94%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SPOT icon
151
Spotify
SPOT
$100B
$2.14M 0.03%
+4,783
New +$2.05M
ANY icon
152
Sphere 3D
ANY
$16M
$2.05M 0.03%
+217,400
New +$2.53M
ZGN icon
153
Zegna
ZGN
$4B
$2M 0.03%
242,000
– –
APP icon
154
Applovin
APP
$116B
$1.99M 0.03%
+6,146
New +$1.55M
INTS icon
155
Intensity Therapeutics
INTS
$11.2M
$1.98M 0.03%
+45,075
New +$3.27M
DPRO
156
Draganfly
DPRO
$172M
$1.93M 0.03%
+480,794
New +$1.58M
ARQQ icon
157
Arqit Quantum
ARQQ
$399M
$1.83M 0.02%
+47,000
New +$697K
MNTS icon
158
Momentus
MNTS
$92.7M
$1.72M 0.02%
+12,171
New +$1.71M
FDMT icon
159
4D Molecular Therapeutics
FDMT
$562M
$1.67M 0.02%
300,000
-36,000
-11% -$283K
BTAI icon
160
BioXcel Therapeutics
BTAI
$27.8M
$1.61M 0.02%
+269,688
New +$2.25M
MTVA
161
MetaVia Inc
MTVA
$7.69M
$1.48M 0.02%
66,240
-10,851
-14% -$294K
MTEKW icon
162
Maris-Tech Ltd Warrants
MTEKW
$1.26M 0.02%
1,261,058
– –
SIG icon
163
Signet Jewelers
SIG
$3.76B
$1.2M 0.02%
+14,808
New +$1.38M
AISP
164
Airship AI Holdings
AISP
$71.3M
$1.12M 0.02%
178,822
-1,121,178
-86% -$3.3M
SRZN icon
165
Surrozen
SRZN
$297M
$1.09M 0.01%
75,694
-63,306
-46% -$672K
CHRN
166
ChronoScale Holdings
CHRN
$3.04B
$1.05M 0.01%
115,043
-29,424
-20% -$362K
LEXX icon
167
Lexaria Bioscience
LEXX
$8.71M
$966K 0.01%
+30,667
New +$1.13M
QUCY
168
Quantum Cyber N.V.
QUCY
$32.8M
$959K 0.01%
+222,000
New +$1.96M
NKTR icon
169
Nektar Therapeutics
NKTR
$2.58B
$952K 0.01%
68,267
+1,600
+2% +$28.2K
HCWB icon
170
HCW Biologics
HCWB
$5.45M
$903K 0.01%
+8,432
New +$984K
PWCM
171
PowerCompute, Inc. Common Stock
PWCM
$1.38M
$791K 0.01%
14,720
+3,640
+33% +$251K
VIVS
172
VivoSim Labs
VIVS
$1.64M
$754K 0.01%
136,554
+35,054
+35% +$178K
MBIO icon
173
Mustang Bio
MBIO
$4.55M
$638K 0.01%
+72,131
New +$796K
GROY.WS icon
174
Gold Royalty Corp Warrants
GROY.WS
$179M
$561K 0.01%
2,200,000
– –
IPDN icon
175
Professional Diversity Network
IPDN
$5.39M
$559K 0.01%
+111,896
New +$821K
5 6
7
8 9

Similar funds

CRC
Curi RMB Capital Chicago, Illinois $5.62B AUM 18.93% 1-Year Est. Return
RMDI
R.M. Davis Inc Portland, Maine $5.63B AUM 21.26% 1-Year Est. Return
F
Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return
EW
Evoke Wealth Los Angeles, California $5.57B AUM 23.85% 1-Year Est. Return
O
Ossiam Paris, France $5.69B AUM 30.95% 1-Year Est. Return
DSC
Donald Smith & Co New York $5.56B AUM 47.13% 1-Year Est. Return
ACM
Altimeter Capital Management Boston, Massachusetts $5.7B AUM 36.74% 1-Year Est. Return
PI
PGGM Investments Zeist, Netherlands $5.7B AUM 17.05% 1-Year Est. Return

Armistice Capital's Q4 2024 Portfolio in Review

As of Q4 2024, Armistice Capital held 321 positions worth $7.33B, up 17% from $6.25B the previous quarter. Its ten largest holdings account for 56% of the portfolio.

Armistice Capital deployed $1.18B of net new capital in Q4 2024, opening 63 new positions and adding to 80 existing holdings. Its largest new stake was Exact Sciences: 1,617,000 shares worth $90.9M.

By sector, the portfolio is most concentrated in Healthcare at 39% of assets, down from 42% a quarter earlier, followed by Consumer Discretionary and Consumer Staples.

On the sell side, the largest reduction was PTC Therapeutics, an estimated $36.7M trimmed.

  • Armistice Capital's largest Q4 2024 buy was Exact Sciences: 1,617,000 shares worth $90.9M.
  • Armistice Capital added most to Neurocrine Biosciences in Q4 2024, an estimated $87.9M increase.
  • Armistice Capital's biggest Q4 2024 reduction was PTC Therapeutics, cutting an estimated $36.7M.
  • Armistice Capital fully exited Alkermes in Q4 2024, selling an estimated $40.5M.
  • Armistice Capital's ten largest holdings make up 56% of its $7.33B portfolio in Q4 2024.
  • Armistice Capital opened 63 new positions and closed 90 in Q4 2024.
  • Armistice Capital's portfolio value rose 17% quarter-over-quarter to $7.33B.

Based on Armistice Capital's 13F filing for Q4 2024, filed 14 Feb 2025.